ISTA Pharmaceuticals, Inc.

170 articles about ISTA Pharmaceuticals, Inc.

• 

  Biotech Movers and Shakers Aug. 27

  8/27/2018

  Who made a splash in the biotech world this week? Here are some notable people.

• ISTA Pharmaceuticals, Inc. to Pay $33.5 Million for Illegal Drug Promotion

  5/28/2013

• Bausch & Lomb Completes the Acquisition of ISTA Pharmaceuticals, Inc.

  6/7/2012

• ISTA Pharmaceuticals, Inc. Highlights PROLENSA(TM) Clinical Data at the 2012 Association for Research in Vision & Ophthalmology Annual Meeting

  5/10/2012

• ISTA Pharmaceuticals, Inc. Reports First Quarter 2012 Financial Results

  5/4/2012

• ISTA Pharmaceuticals, Inc. Reports Positive Results From Phase 2 Trial Of BEPOSONE Nasal Spray

  5/1/2012

• Bausch & Lomb and ISTA Pharmaceuticals, Inc. Announce Early Termination of Hart-Scott-Rodino Waiting Period

  4/24/2012

• ISTA Pharmaceuticals, Inc. Highlights PROLENSA(TM) Clinical Data at the 2012 American Society of Cataract & Refractive Surgery Symposium and Congress

  4/23/2012

• The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of ISTA Pharmaceuticals, Inc. in Connection with the Sale of the Company to Bausch & Lomb

  3/29/2012

• Harwood Feffer LLP Announces Investigation of ISTA Pharmaceuticals, Inc.

  3/28/2012

• ISTA Pharmaceuticals, Inc. Announces Issuance of U.S. Patent for PROLENSA(TM)

  3/27/2012

• Block & Leviton LLP Investigates ISTA Pharmaceuticals, Inc.'s Board of Directors for Possible Breaches of Fiduciary Duty

  3/27/2012

• Bausch & Lomb to Buy ISTA Pharmaceuticals, Inc. for $500 Million

  3/27/2012

• ISTA Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2011 Financial Results

  2/23/2012

• Effimune With Its Lead Drug Candidate FR104, Has Been Selected Through the Consortium TRIAD, Under the European Union FP7 Funding Program

  2/13/2012

• ISTA Pharmaceuticals, Inc. Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2011 Financial Results

  2/9/2012

• Valeant Pharmaceuticals International Withdraws Bid for ISTA Pharmaceuticals, Inc.

  1/30/2012

• ISTA Pharmaceuticals, Inc.'s Board Reiterates Commitment to Maximizing Shareholder Value Through Strategic Review Process

  1/30/2012

• ISTA Pharmaceuticals, Inc. Completes Patient Enrollment in Phase 2 Clinical Study of BEPOSONE(TM) (Bepotastine Besilate - Steroid Combination Nasal Spray) for the Treatment of Symptoms Associated With Seasonal Allergic Rhinitis

  1/30/2012

• Valeant Pharmaceuticals International Makes Improved Bid to Acquire ISTA Pharmaceuticals, Inc.

  1/17/2012